Level C· Early human research exploring benefitsProspective StudyEurope PMCOpen access

Full spectrum flow cytometry reveals mesenchymal heterogeneity in first trimester placentae and phenotypic convergence in culture, providing insight into the origins of placental mesenchymal stromal cells

Boss AL., Damani T., Wickman TJ., Chamley LW., James JL., Brooks AES.

Prospective Study on Hip, published in Elife (2022) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Elife (2022)
Reported sample size
—
Source database
Europe PMC
PMID
35920626
PMCID
PMC9371602
DOI
10.7554/elife.76622
Citations
14

Abstract (original English)

Single-cell technologies (RNA-sequencing, flow cytometry) are critical tools to reveal how cell heterogeneity impacts developmental pathways. The placenta is a fetal exchange organ, containing a heterogeneous mix of mesenchymal cells (fibroblasts, myofibroblasts, perivascular, and progenitor cells). Placental mesenchymal stromal cells (pMSC) are also routinely isolated, for therapeutic and research purposes. However, our understanding of the diverse phenotypes of placental mesenchymal lineages, and their relationships remain unclear. We designed a 23-colour flow cytometry panel to assess mesenchymal heterogeneity in first-trimester human placentae. Four distinct mesenchymal subsets were identified; CD73 + CD90 + mesenchymal cells, CD146 + CD271 + perivascular cells, podoplanin + CD36 + stromal cells, and CD26 + CD90 + myofibroblasts. CD73 + CD90 + and podoplanin + CD36+ cells expressed markers consistent with cultured pMSCs, and were explored further. Despite their distinct ex-vivo phenotype, in culture CD73 + CD90 + cells and podoplanin + CD36 + cells underwent phenotypic convergence, losing CD271 or CD36 expression respectively, and homogenously exhibiting a basic MSC phenotype (CD73 + CD90 + CD31 - CD144 - CD45 - ). However, some markers (CD26, CD146) were not impacted, or differentially impacted by culture in different populations. Comparisons of cultured phenotypes to pMSC

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
Cells, CulturedMesenchymal Stem CellsPlacentaHumansFlow CytometryCell DifferentiationPregnancyPregnancy Trimester, FirstPhenotypeFemale

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research